Michael Barbella, Managing Editor06.26.23
Implanet has introduced the MIS range in Europe. A result of joint developments with its partner Sanyou Medical, the product is a minimally invasive pedicle screw positioning system
“With the launch of this range of minimally invasive pedicle screws, we are reaffirming our ability to innovate by developing products that provide a response to both surgeons’ requirements and their patients’ pathologies, thus significantly reducing the trauma open surgery can cause," Implanet CEO Ludovic Lastennet said. 'This first innovation in partnership with Sanyou Medical also illustrates the strength of this alliance concluded at the end of 2022 with one of China’s foremost manufacturers of medical devices. We have been able to swiftly share our respective expertise to develop this first range, which supplements and strengthens our positioning in the treatment of adult spine disorders.”
Minimally invasive spine surgery was developed to treat spinal pathologies while limiting tissue damage, Bleeding, and post operative infection, with the goal of faster recovery.
The pedicle screw system proposed by Implanet consists of latest generation implants and a single set of instruments. The range of pedicle screws and associated implants provides surgeons with a comprehensive solution for treating degenerative, traumatic or tumoral spine pathologies.
Within the framework of this European commercial launch, Implanet has initiated system demonstrations in various health centers in Europe and has already received its first orders this month.
At May 31, 2023, Implanet had a cash position of €1.51 million. The company is actively studying several financing solutions in order to support the commercial development of its medical devices.
Founded in 2007, Implanet imanufactures implants for orthopedic surgery and distributes medical technology equipment. Its activity revolves around a solution for improving spinal pathology treatment complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ has obtained U.S Food and Drug Administration 510(k) regulatory clearance, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered into a commercial, technological and financial partnership with Sanyou Medical, China's second largest medical device manufacturer. Implanet employs 43 workers and recorded a consolidated revenue of €8 million in 2022. Based near Bordeaux in France, Implanet opened a U.S. subsidiary in Boston in 2013. Implanet is listed on the Euronext Growth market in Paris.
“With the launch of this range of minimally invasive pedicle screws, we are reaffirming our ability to innovate by developing products that provide a response to both surgeons’ requirements and their patients’ pathologies, thus significantly reducing the trauma open surgery can cause," Implanet CEO Ludovic Lastennet said. 'This first innovation in partnership with Sanyou Medical also illustrates the strength of this alliance concluded at the end of 2022 with one of China’s foremost manufacturers of medical devices. We have been able to swiftly share our respective expertise to develop this first range, which supplements and strengthens our positioning in the treatment of adult spine disorders.”
Minimally invasive spine surgery was developed to treat spinal pathologies while limiting tissue damage, Bleeding, and post operative infection, with the goal of faster recovery.
The pedicle screw system proposed by Implanet consists of latest generation implants and a single set of instruments. The range of pedicle screws and associated implants provides surgeons with a comprehensive solution for treating degenerative, traumatic or tumoral spine pathologies.
Within the framework of this European commercial launch, Implanet has initiated system demonstrations in various health centers in Europe and has already received its first orders this month.
At May 31, 2023, Implanet had a cash position of €1.51 million. The company is actively studying several financing solutions in order to support the commercial development of its medical devices.
Founded in 2007, Implanet imanufactures implants for orthopedic surgery and distributes medical technology equipment. Its activity revolves around a solution for improving spinal pathology treatment complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ has obtained U.S Food and Drug Administration 510(k) regulatory clearance, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered into a commercial, technological and financial partnership with Sanyou Medical, China's second largest medical device manufacturer. Implanet employs 43 workers and recorded a consolidated revenue of €8 million in 2022. Based near Bordeaux in France, Implanet opened a U.S. subsidiary in Boston in 2013. Implanet is listed on the Euronext Growth market in Paris.